Innovent Biologics, Inc. (IVBXF) Financials

IVBXF Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 6.1 billion 3.0 billion
Dec. 31, 2025 5.3 billion 2.5 billion
June 30, 2025 3.3 billion 1.3 billion
Dec. 31, 2024 3.0 billion 1.2 billion

IVBXF Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 ? 56.6 million
Dec. 31, 2025 1.3 billion ?
June 30, 2025 29.5 million 47.8 million
Dec. 31, 2024 169.4 million 35.5 million

IVBXF Net Income

No data available :(

IVBXF Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 2.9 billion 259.5 million 4.7 million
Dec. 31, 2025 2.6 billion 284.5 million 5.3 million
June 30, 2025 1.3 billion 315.9 million 1.1 million
Dec. 31, 2024 1.1 billion 330.5 million 1.9 million

IVBXF Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 265.1 million
Dec. 31, 2025 118.5 million
June 30, 2025 236.6 million
Dec. 31, 2024 223.6 million

IVBXF Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 244.4 million 541.5 million -
Dec. 31, 2025 32.6 million 227.1 million 537.3 million -
June 30, 2025 14.3 million 140.8 million 393.2 million 331.5 million
Dec. 31, 2024 36.5 million 175.6 million 395.4 million 338.1 million

IVBXF Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 1.3 billion 188.2 million
Dec. 31, 2025 996.3 million 129.7 million
June 30, 2025 831.0 million 188.9 million
Dec. 31, 2024 749.3 million 180.5 million

IVBXF

Price: $12.14

52 week price:
9.10
15.01

Earnings Per Share: 0.07 USD

P/E Ratio: 203.89

Exchange: PNK

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 22.3 billion

Links: